CBR Systems, Inc., also known as Cord Blood Registry Systems, operates a cord blood stem cell bank that serves families in the United States and internationally. It focuses on advancing the clinical application of cord blood stem cells by partnering with research institutions. The company offers collecting, processing, and long-term cryopreservation of newborn cord blood and tissue stem cell units that are contained in the umbilical cord blood of newborns. It also creates collection devices designed for cord blood stem cells; and CellAdvantage, a collection kit that is designed to preserve and to help the safe delivery of the blood and/or tissue. The company has strategic collaboration with ...
1200 Bayhill Drive
San Bruno, CA 94066
Founded in 1992
AMAG Pharmaceuticals, Inc., CBR Systems, Inc. - M&A Call
Jun 29 15
To discuss definitive agreement to acquire Cord Blood Registry
Cord Blood Registry Announces Formation of Scientific & Medical Advisory Board
Feb 3 15
Cord Blood Registry announced the establishment of a Scientific and Medical Advisory Board (SMAB). Composed of internationally renowned stem cell experts, the SMAB will provide input and guidance to help advance CBR's mission to expand the scope of newborn stem cell therapies that may be available to patients and their families. The founding members of the SMAB are Dr. Charles Cox, Dr. Mahendra Rao, Dr. Leslie Silberstein and Dr. Alan Trounson. Dr. Rao will serve as the inaugural chairman of the SMAB, and he will also be acting as CBR's chief clinical and regulatory advisor. Mahendra Rao, MD, PhD, is the Vice President for Regenerative Medicine at The New York Stem Cell Foundation Research Institute. Previously, Dr. Rao served as the Director of the National Institute of Health (NIH) Center for Regenerative Medicine. Charles S. Cox, Jr, MD, is the George and Cynthia Mitchell Distinguished Chair in Neurosciences, as well as the Director of the Children's Program in Regenerative Medicine and Professor of the Department of Pediatric Surgery at the University of Texas Medical School at Houston. Dr. Cox also directs the Pediatric Trauma Program at the University of Texas-Houston/Children'sMemorial Hermann Hospital in the Texas Medical Center. Leslie Silberstein, MD, is a Professor of Pathology at Harvard Medical School. Dr. Silberstein also serves as the Director of the Joint Program in Transfusion Medicine at Children's Hospital Boston, Brigham and Women's Hospital, and the Dana-Farber Cancer Institute. In addition, Dr. Silberstein is the Director of the Center for Human Cell Therapy at the Immune Disease Institute/Programs in Cellular and Molecular Medicine at Children's Hospital Boston. Previously, Dr. Silberstein established an academic transfusion medicine division with the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. Alan Trounson, PhD, MSc, is an Emeritus Professor at Monash University, a Distinguished Scientist at Monash-Prince Henry's Institute for Medical Research, and a Fellow of the Australian Academy of Technological Sciences and Engineering in Melbourne, Australia. Dr. Trounson previously served as President of The California Institute of Regenerative Medicine (CIRM), the large scientific funding body for stem cell research in the world. Prior to joining CIRM in January 2008, Dr. Trounson was Professor of Stem Cell Sciences and Director of the Immunology and Stem Cell Laboratories at Monash University.
China Cord Blood Corporation and Cord Blood Registry Enter into Memorandum of Understanding Regarding Strategic Collaboration in China and the United States
Jan 28 15
China Cord Blood Corporation and Cord Blood Registry entered into a memorandum of understanding regarding their strategic collaboration in China and the United States. The two prominent cord blood banks will share data on cord blood collection, processing and storage to advance international standards. The companies will also work together under the memorandum, to develop a family disease registry for China Cord Blood Corporation's clients in China and jointly support newborn stem cell-related clinical trials in the U.S. and China. This important collaborative effort achieves a milestone in bringing the two large cord blood banks in the world into close concert for the benefit of their client families, future patients and the stem cell clinical research community. It also presents an opportunity to aid families impacted by certain diseases across an international and racially diverse population. In the aggregate, the two companies have collected and stored samples from an estimated 1 million newborn children worldwide, accounting for nearly half of all cord blood units preserved globally. Through this collaboration, they will be able to share its expertise and resources and improve mutual access to crucial research in China and the U.S. This partnership is a significant step toward raising global awareness of the importance of newborn cord blood hematopoietic stem cell research.